Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AKBANASDAQ:CPRXNASDAQ:MORNASDAQ:MTSR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKBAAkebia Therapeutics$3.97+7.6%$2.44$0.80▼$4.00$969.13M0.853.08 million shs8.17 million shsCPRXCatalyst Pharmaceuticals$25.87+2.0%$23.64$14.75▼$26.16$3.16B0.721.11 million shs1.20 million shsMORMorphoSys$18.96$18.96$4.18▼$19.50$2.86B1.21.02 million shsN/AMTSRMetsera$27.49-4.1%$22.96$12.30▼$32.81$2.89BN/A866,695 shs391,840 shs10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKBAAkebia Therapeutics+7.59%+31.02%+62.57%+108.95%+260.91%CPRXCatalyst Pharmaceuticals+2.01%+3.94%+10.27%+17.81%+58.61%MORMorphoSys0.00%0.00%0.00%0.00%+4.35%MTSRMetsera-4.12%+3.70%+18.64%+7.93%+2,748,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAKBAAkebia Therapeutics4.2733 of 5 stars4.61.00.04.03.10.80.6CPRXCatalyst Pharmaceuticals4.8749 of 5 stars3.63.00.03.93.43.32.5MORMorphoSysN/AN/AN/AN/AN/AN/AN/AN/AMTSRMetseraN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAKBAAkebia Therapeutics 3.20Buy$6.7570.03% UpsideCPRXCatalyst Pharmaceuticals 3.25Buy$32.8326.92% UpsideMORMorphoSys 0.00N/AN/AN/AMTSRMetsera 3.00Buy$47.0070.97% UpsideCurrent Analyst Ratings BreakdownLatest AKBA, CPRX, MTSR, and MOR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/5/2025CPRXCatalyst PharmaceuticalsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy6/4/2025AKBAAkebia TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$8.004/28/2025AKBAAkebia TherapeuticsLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy4/28/2025AKBAAkebia TherapeuticsLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$7.004/4/2025AKBAAkebia TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.50 ➝ $7.504/1/2025AKBAAkebia TherapeuticsJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$6.003/14/2025AKBAAkebia TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$4.00 ➝ $6.003/14/2025AKBAAkebia TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.50 ➝ $7.50(Data available from 6/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAKBAAkebia Therapeutics$184.91M5.64N/AN/A($0.16) per share-24.81CPRXCatalyst Pharmaceuticals$534.65M5.90$2.41 per share10.72$3.30 per share7.84MORMorphoSys$238.28M11.99N/AN/A$0.35 per share54.17MTSRMetseraN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAKBAAkebia Therapeutics-$51.92M-$0.21N/AN/AN/A-27.07%N/A-20.57%8/6/2025 (Estimated)CPRXCatalyst Pharmaceuticals$71.41M$1.5721.9212.153.3131.01%40.79%34.87%8/6/2025 (Estimated)MORMorphoSys-$205.35M-$3.48N/AN/AN/A-226.79%-694.31%-22.55%N/AMTSRMetseraN/AN/A0.00∞N/AN/AN/AN/AN/ALatest AKBA, CPRX, MTSR, and MOR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025MTSRMetseraN/A-$1.03N/A-$1.03N/AN/A5/8/2025Q1 2025AKBAAkebia Therapeutics-$0.03$0.03+$0.06$0.03$44.88 million$57.34 million3/26/2025N/AMTSRMetseraN/A-$3.52N/A-$3.52N/AN/A3/13/2025Q4 2024AKBAAkebia Therapeutics-$0.05-$0.10-$0.05-$0.10$37.36 million$46.50 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAKBAAkebia TherapeuticsN/AN/AN/AN/AN/ACPRXCatalyst PharmaceuticalsN/AN/AN/AN/AN/AMORMorphoSysN/AN/AN/AN/AN/AMTSRMetseraN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAKBAAkebia TherapeuticsN/A1.521.21CPRXCatalyst PharmaceuticalsN/A5.114.92MORMorphoSys4.981.381.38MTSRMetseraN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAKBAAkebia Therapeutics33.92%CPRXCatalyst Pharmaceuticals79.22%MORMorphoSys18.38%MTSRMetseraN/AInsider OwnershipCompanyInsider OwnershipAKBAAkebia Therapeutics3.00%CPRXCatalyst Pharmaceuticals10.40%MORMorphoSys0.05%MTSRMetseraN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAKBAAkebia Therapeutics430262.64 million209.24 millionOptionableCPRXCatalyst Pharmaceuticals80121.98 million106.15 millionOptionableMORMorphoSys730150.62 million150.55 millionNot OptionableMTSRMetsera81105.06 millionN/AN/AAKBA, CPRX, MTSR, and MOR HeadlinesRecent News About These CompaniesMetsera (NASDAQ:MTSR) Trading Down 3.7% - Here's WhyJune 6 at 11:58 AM | marketbeat.comMetsera to Present New Research Highlighting the Breadth and Momentum of its Next-Generation Obesity Portfolio at the 85th Scientific Sessions of the American Diabetes Association®June 5 at 7:30 AM | globenewswire.comMetsera (NASDAQ:MTSR) Shares Up 7.6% - Should You Buy?June 3, 2025 | marketbeat.comMetsera (NASDAQ:MTSR) Trading Down 6.9% - Here's What HappenedJune 1, 2025 | americanbankingnews.comMetsera (NASDAQ:MTSR) Stock Price Down 6.9% - Should You Sell?May 31, 2025 | marketbeat.comMetsera (NASDAQ:MTSR) Trading 8.6% Higher - Here's What HappenedMay 29, 2025 | marketbeat.comCantor Fitzgerald maintains overweight on Metsera sharesMay 29, 2025 | uk.investing.comMetsera (NASDAQ:MTSR) Trading 13.4% Higher - Here's What HappenedMay 14, 2025 | marketbeat.comMetsera (NASDAQ:MTSR) Issues Quarterly Earnings ResultsMay 14, 2025 | marketbeat.comMetsera, Inc. Reports First Quarter 2025 Financial Results and Progress on Clinical Trials for Obesity TreatmentsMay 13, 2025 | nasdaq.comMetsera, Inc.: Metsera Reports First Quarter 2025 Financial Results and Continued Portfolio ProgressMay 12, 2025 | finanznachrichten.deMetsera Reports First Quarter 2025 Financial Results and Continued Portfolio ProgressMay 12, 2025 | globenewswire.comMetsera Rings the Opening BellMay 9, 2025 | nasdaq.comMetsera Rings the Nasdaq Stock Market Opening BellMay 9, 2025 | nasdaq.comMetsera: A Must-Add To Your Watchlist Thanks To GLP-1 Obesity PromiseMay 9, 2025 | seekingalpha.comMetsera to Present at Bank of America 2025 Global Healthcare ConferenceMay 8, 2025 | globenewswire.comMetsera (NASDAQ:MTSR) Stock Price Down 7.6% - What's Next?May 7, 2025 | marketbeat.comMetsera Inc. appoints new director and legal officerApril 30, 2025 | investing.comMetsera, Inc. Appoints New Board Member and Legal OfficerApril 28, 2025 | tipranks.comBank of America Securities Remains a Buy on Metsera, Inc. (MTSR)April 9, 2025 | markets.businessinsider.comMetsera, Inc.: Metsera Reports Fourth Quarter and Full Year 2024 Financial Results and Continued Portfolio ProgressMarch 27, 2025 | finanznachrichten.deNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeBullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsBy Thomas Hughes | May 27, 2025View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsIntel’s Turnaround May Be the Best Bet No One’s WatchingBy Jeffrey Neal Johnson | May 30, 2025View Intel’s Turnaround May Be the Best Bet No One’s WatchingNavitas Soars on NVIDIA Deal: Breaking Down Its Tech and OutlookBy Leo Miller | May 27, 2025View Navitas Soars on NVIDIA Deal: Breaking Down Its Tech and Outlook2 Red-Hot Stocks With High RSIs and More Upside to ComeBy Sam Quirke | May 27, 2025View 2 Red-Hot Stocks With High RSIs and More Upside to ComeAKBA, CPRX, MTSR, and MOR Company DescriptionsAkebia Therapeutics NASDAQ:AKBA$3.97 +0.28 (+7.59%) Closing price 06/6/2025 04:00 PM EasternExtended Trading$4.00 +0.02 (+0.63%) As of 06/6/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.Catalyst Pharmaceuticals NASDAQ:CPRX$25.87 +0.51 (+2.01%) Closing price 06/6/2025 04:00 PM EasternExtended Trading$26.06 +0.18 (+0.72%) As of 06/6/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.MorphoSys NASDAQ:MOR$18.96 0.00 (0.00%) As of 06/5/2025MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company's product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for renal autoimmune diseases and relapsed/refractory multiple myeloma; Ianalumab, a candidate in Phase 3 clinical trials for Sjögren's disease, lupus nephritis, and other autoimmune diseases; Abelacimab that is in Phase 3 trials for venous thromboembolism prevention and cancer-associated thrombosis; Setrusumab, which is in Phase 2/3 trials for osteogenesis imperfecta; and Bimagrumab, a product candidate in Phase 2b trials for adult obesity. It also develops MOR210/TJ210/HIB210 that is in Phase 1 clinical trials for relapsed or refractory advanced solid tumors; and NOV-8, a candidate in Phase 2 trials for the treatment of pulmonary sarcoidosis and dermatitis. The company has collaboration and licensing agreements with I-Mab Biopharma, Novartis, Anthos Therapeutics, Ultragenyx, Mereo BioPharma, Lilly, Human Immunology Biosciences, Inc. Incyte Corporation, and Xencor, Inc. MorphoSys AG was founded in 1992 and is headquartered in Planegg, Germany.Metsera NASDAQ:MTSR$27.49 -1.18 (-4.12%) As of 06/6/2025 04:00 PM EasternMetsera, Inc. is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o. The company was founded by Clive A. Meanwell in 2022 and is headquartered in New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/02 - 06/06 This Banking Giant Just Got a $90 Price Target Upgrade Broadcom Slides on Solid Earnings, AI Outlook Still Strong The Market’s Silent Warning: What Bonds and Gold Reveal MongoDB Affirms Outlook and Accelerates Stock Price Reversal Are NVIDIA's Ethernet Wins Signs of Hope or Horror for Arista? AT&T: Is This Telecom Giant a Buy or a Bye for Your Portfolio? Why Visa's Innovation Engine Keeps It a Top Portfolio Pick Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
